[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![vixflatline Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1728468154400100352.png) VIX [@vixflatline](/creator/twitter/vixflatline) on x 3406 followers
Created: 2025-07-15 21:28:10 UTC

China's biotech ascent isn't hype, it's a regulatory blitz yielding 2x faster preclinical timelines and dominance in ADCs, bispecifics, and T-cell engagers, with Jiangsu Hengrui now topping global innovative drug output. 

As US firms ink $48B in licenses from the East, our bureaucratic drag ensures we'll be importing cures, not exporting them. 

Deregulate now or watch the pipeline pivot permanently. 🐢🐢


XX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1945233957638803464/c:line.svg)

**Related Topics**
[$48b](/topic/$48b)
[ink](/topic/ink)
[dominance](/topic/dominance)
[faster](/topic/faster)
[vix](/topic/vix)
[$issc](/topic/$issc)

[Post Link](https://x.com/vixflatline/status/1945233957638803464)